Prosecution Insights
Last updated: April 19, 2026
Application No. 18/257,739

COMPOSITIONS FOR ELASTOMERIC COMPOUNDS AND TYRES FOR VEHICLES COMPRISING REVERSIBLE CROSS-LINKING AGENT

Non-Final OA §103§112
Filed
Jun 15, 2023
Examiner
PEPITONE, MICHAEL F
Art Unit
1767
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Pirelli Tyre S P A
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
96%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
865 granted / 1165 resolved
+9.2% vs TC avg
Strong +22% interview lift
Without
With
+22.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
52 currently pending
Career history
1217
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
40.9%
+0.9% vs TC avg
§102
24.8%
-15.2% vs TC avg
§112
19.8%
-20.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1165 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Objections Claim 25 and 32 are objected to because of the following informalities: “metacryl” should be “methacryl”. Appropriate correction is required. Claim 34 is objected to because of the following informalities: “lanthanidesCu2+,” should be ““lanthanides, Cu2+,”. Appropriate correction is required. Claim 42 is objected to because of the following informalities: “compound,, to” should be “compound, to”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 34-35 and 42-43 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 34 recites the broad recitation alkaline earth metals, and the claim also recites Ca2+ and Mg2+ which is the narrower statement of the range/limitation. In the present instance, claim 34 recites the broad recitation transition metals, and the claim also recites Cu2+, Fe2+, Zn2+, and Ru3+ which is the narrower statement of the range/limitation. In the present instance, claim 34 recites the broad recitation lanthanides, and the claim also recites Tb3+ and Eu3+ which is the narrower statement of the range/limitation. In the present instance, claim 35 recites the broad recitation weakly coordinating anion, and the claim also recites tosylate, bistriflimidate or a triflate which is the narrower statement of the range/limitation. In the present instance, claim 42 recites the broad recitation weakly coordinating anion, and the claim also recites tosylate, bistriflimidate or a triflate which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Accordingly, dependent claim 43 is indefinite. For the purpose of examination, claim 34 will be interpreted as the metal cation is selected from the group consisting Cu2+, Fe2+, Zn2+, Mg2+ Ca2+, Ru3+, Tb3+, and Eu3+. For the purpose of examination, claims 35 and 42 will be interpreted as the weakly coordinating anion is selected from the group consisting of tosylate, bistriflimidate and triflate. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 22-32, 34, 37-41, and 44-46 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mruk et al. (US 2014/0148555). Regarding claims 22-26, 28-32, 34, and 40: Mruk et al. (US ‘555) discloses rubber compositions for tires [abstract], wherein Example 4 [Ex. 4; 0121-0137] prepares 4'-(4-mercaptomethylphenyl)-2,2':6,2''-terpyridine (VIII) (355.46 g/mol) for functionalization of a styrene-butadiene rubber. Mruk et al. (US ‘555) discloses 1 g of rubber was functionalized with 1.40 g 4'-(4-mercaptomethylphenyl)-2,2':6,2''-terpyridine (VIII) (corresponding to 140 phr of VIII) [Ex. 4; 0096-0098; 0136]. Mruk et al. (US ‘555) discloses Example 6 [Ex. 6; 0140-0141] prepares a mixture comprising 0.03 g of the functionalized rubber of Ex. 4 and 0.02 g of RuCl3 (207.42 g/mol) (corresponding to 67 phr of RuCl3) [Ex. 6; 0140-0141]. Mruk et al. (US ‘555) discloses the rubber composition can contain about 10 to about 150 phr silica [0071; 0073]. Mruk et al. (US ‘555) discloses the rubber composition can contain 0.5 to 8 phr sulfur vulcanizing agent [0085]. Mruk et al. (US ‘555) does not specifically disclose Examples 4 and 6 containing about 10 to about 150 phr silica and 0.5 to 8 phr sulfur vulcanizing agent. However, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have included about 10 to about 150 phr silica and 0.5 to 8 phr sulfur vulcanizing agent based on the invention of Mruk et al. (US ‘555), and would have been motivated to do so since Mruk et al. (US ‘555) suggests that the composition can contain about 10 to about 150 phr silica, and 0.5 to 8 phr sulfur vulcanizing agent [0073; 0085]. Additionally, “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (citations omitted) [see MPEP 2144.06]. Note 4'-(4-mercaptomethylphenyl)-2,2':6,2''-terpyridine (VIII): PNG media_image1.png 240 290 media_image1.png Greyscale [Ex. 4; 0121-0135]. Regarding claim 27: Mruk et al. (US ‘555) discloses Ex. 2 prepares 6-(2,2';6',2''-terpyridin-4'-ylsulfanyl)hexane-1-thiol (VI) [Ex. 2; 0106-0113]; i.e. substitute (VIII) with (VI) in Examples 4&6. An express suggestion to substitute one equivalent component or process for another is not necessary to render such substitution obvious. In re Fout, 675 F.2d 297, 213 USPQ 532 (CCPA 1982). [see MPEP 2144.06]. Note 6-(2,2';6',2''-terpyridin-4'-ylsulfanyl)hexane-1-thiol (VI): PNG media_image2.png 180 340 media_image2.png Greyscale [Ex. 2; 0106-0113]. Regarding claims 37-38: Mruk et al. (US ‘555) discloses the rubber composition can contain a metal ion in an amount sufficient to complex with the functionalized elastomer, as well as an excess of, or less than the metal ion depending on the desired effect [0060-0062]. Mruk et al. (US ‘555) does not specifically disclose 0.5 phr to 20 phr of (VIII); does not specifically disclose 0.2 to 7 phr of metal ion. However, differences in concentration will not support the patentability of subject mat-ter encompassed by the prior art unless there is evidence indicating such concentration is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to dis-cover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382; In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997) [see MPEP 2144.05]. Regarding claim 39: Mruk et al. (US ‘555) discloses a molar ratio of (VIII):RuCl3 of 0.51:1 {as calculated by examiner} [Ex. 6; 0140-0141]. Regarding claim 41 and 44-46: Mruk et al. (US ‘555) discloses the rubber composition is mixed in two stages and vulcanized to afford a tire [0087-0090], wherein the tire rubber component is a tread and/or sidewall [0088]. Allowable Subject Matter Claims 33 and 36 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 35 and 42-43 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: Mruk et al. (US 2014/0148555) does not disclose a crosslinking agent having B as -O-(CH2)1-11- and C as 2,6-bis(1-methylbenzimidazol-2-yl)-pyridin-4-yl [instant claim 33]. Mruk et al. (US ‘555) does not disclose zinc triflate as the metal ion [instant claim 36]. While Mruk et al. (US ‘555) discloses the rubber composition is mixed in two stages, including a non-productive stage followed by a productive stage [0087], wherein the final curatives including vulcanizing agents are mixed in the final stage (productive stage) [0087], Mruk et al. (US ‘555) does not disclose the metal ion [0061-0062] including a tosylate, bistriflimidate or triflate as the anion [instant claims 35, 42]. See attached form PTO-892. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL F PEPITONE whose telephone number is (571)270-3299. The examiner can normally be reached on 7:00 AM - 3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mark Eashoo can be reached on 571-272-1197. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL F PEPITONE/Primary Examiner, Art Unit 1767
Read full office action

Prosecution Timeline

Jun 15, 2023
Application Filed
Jan 10, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600875
OIL-BASED INK COMPOSITION FOR BALLPOINT PENS AND BALLPOINT PEN EMPLOYING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12595370
POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT
2y 5m to grant Granted Apr 07, 2026
Patent 12595371
CONTACT LENS WITH IMPROVED VISION BREAK-UP TIME
2y 5m to grant Granted Apr 07, 2026
Patent 12589055
DENTAL COMPOSITION
2y 5m to grant Granted Mar 31, 2026
Patent 12584027
CURABLE ORGANOPOLYSILOXANE COMPOSITION, AND OPTICAL MEMBER FORMED FROM CURED PRODUCT OF SAME
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
96%
With Interview (+22.2%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 1165 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month